EVLO News and Press, Evelo Biosciences Inc. From 09/07/22

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad a...

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that the Company will participate in a f...

Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Conference Call August 11, 2022 07:30 ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Ara Darzi - Chairman Conference Call Participants Chris Howerton - J...

Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q2 2022 Earnings Call Aug 11, 2022 , 7:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript

Evelo Biosciences ( NASDAQ: EVLO ) announced the succession plan for Simba Gill, to transition from his roles as CEO and President to the role of Chair of the Board and return to Flagship Pioneering to help launch, grow, and guide bioplatform companies. The company bo...

Evelo Biosciences press release ( NASDAQ: EVLO ): Q2 GAAP EPS of -$0.40 beats by $0.03 . As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021. For further details see: Evelo Bio...

– Simba Gill to transition to Chair of the Board of Directors – – Lord Ara Darzi will become Lead Independent Director – – Board has retained Spencer Stuart for Chief Executive Officer search – CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEW...

– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end – – Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 – – Phase 2 data for EDP2939 in psoriasis expected in 2H 20...

CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and l...

Evelo Biosciences ( NASDAQ: EVLO ) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals. ...